all report title image
  • Published In : Aug 2023
  • Code : CMI989
  • Pages : 197
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

Biological drugs refer to therapeutic products derived from living organisms or contain components of living organisms. Biological drugs are widely used in the treatment of number of diseases including diabetes, plaque psoriasis, arthritis, Crohn’s disease, and ulcerative colitis.

Oral biologics products refer to the biological drugs taken from oral disease indication. Currently, majority of biological drugs are administrated by parenteral route and only guanylate cyclase-c agonist class of drug is approved oral biologics in market.

However, key players in the market are involved in development of orally administered glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, and various hormone for different indications.

Market Dynamics

Increasing number of inorganic strategies such as collaborations, partnerships, mergers, and acquisition by key players is a major factor driving growth of the market. For instance, in February 2021, Biocon Limited announced merger with International Diabetes Federation (IDF), an insulin biosimilar company, and the merger focuses on the research and development of Biocon’s biologics segment and promote the affordable access of insulin products manufactured by Biocon to the diabetes patients globally.

Key features of the study:

  • This report provides in-depth analysis of the global oral biologics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global oral biologics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc. and Allena Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global oral biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oral biologics market

Detailed Segmentation:

  • Global Oral Biologics Market, By Drug Class:
    • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
    • Hormone
    • Recombinant Enzyme
    • Guanylate Cyclase-C Agonist
    • Somatostatin Analogue
    • Others
  • Global Oral Biologics Market, By Disease Indication:
    • Diabetes
    • Hyperoxaluria
    • Acromegaly
    • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
    • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
  • Global Oral Biologics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Oral Biologics Market, By Region:
    • North America
      • By Drug Class
        • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
        • Hormone
        • Recombinant Enzyme
        • Guanylate Cyclase-C Agonist
        • Somatostatin Analogue
        • Others
      • By Disease Indication
        • Diabetes
        • Hyperoxaluria
        • Acromegaly
        • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
        • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Class
        • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
        • Hormone
        • Recombinant Enzyme
        • Guanylate Cyclase-C Agonist
        • Somatostatin Analogue
        • Others
      • By Disease Indication
        • Diabetes
        • Hyperoxaluria
        • Acromegaly
        • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
        • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class
        • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
        • Hormone
        • Recombinant Enzyme
        • Guanylate Cyclase-C Agonist
        • Somatostatin Analogue
        • Others
      • By Disease Indication
        • Diabetes
        • Hyperoxaluria
        • Acromegaly
        • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
        • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class
        • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
        • Hormone
        • Recombinant Enzyme
        • Guanylate Cyclase-C Agonist
        • Somatostatin Analogue
        • Others
      • By Disease Indication
        • Diabetes
        • Hyperoxaluria
        • Acromegaly
        • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
        • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class
        • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
        • Hormone
        • Recombinant Enzyme
        • Guanylate Cyclase-C Agonist
        • Somatostatin Analogue
        • Others
      • By Disease Indication
        • Diabetes
        • Hyperoxaluria
        • Acromegaly
        • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
        • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class
        • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
        • Hormone
        • Recombinant Enzyme
        • Guanylate Cyclase-C Agonist
        • Somatostatin Analogue
        • Others
      • By Disease Indication
        • Diabetes
        • Hyperoxaluria
        • Acromegaly
        • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
        • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Novo Nordisk A/S *
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Biocon Limited
    • Oramed Pharmaceuticals, Inc.
    • Rani Therapeutics
    • Entera Bio Ltd.
    • AbbVie Inc.
    • Enteris BioPharma, Inc.
    • Chiasma, Inc.
    • Allena Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Disease Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Recent Test Launches
    • Epidemiology
    • Merger, Acquisition, and Collaborations
    • Regulatory Scenario
    • Key Developments
    • PEST Analysis
  4. Global Oral Biologics Market-COVID-19 Impact Analysis
    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Supply and Demand
  5. Global Oral Biologics Market, By Drug Class, 2018-2030, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018-2030
      • Segment Trends
    • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
      • Segment Trends
    • Hormone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
      • Segment Trends
    • Recombinant Enzyme
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
      • Segment Trends
    • Guanylate Cyclase-C Agonist
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
      • Segment Trends
    • Somatostatin Analogue
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
      • Segment Trends
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
      • Segment Trends
  6. Global Oral Biologics Market, By Disease Indication, 2018-2030, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018-2030
      • Segment Trends
    • Diabetes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
      • Segment Trends
    • Hyperoxaluria
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
      • Segment Trends
    • Acromegaly
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
      • Segment Trends
    • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
      • Segment Trends
    • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
      • Segment Trends
  7. Global Oral Biologics Market, By Distribution Channel, 2018-2030, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018-2030
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  8. Global Oral Biologics Market, By Region, 2018-2030, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018-2030
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
      • Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
      • Market Size and Forecast, By Country, Y-o-Y Growth and By Country,  2018-2030, (US$ Bn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
      • Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
      • Market Size and Forecast, By Country, Y-o-Y Growth and By Country,  2018-2030, (US$ Bn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
      • Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
      • Market Size and Forecast, By Country, Y-o-Y Growth and By Country,  2018-2030, (US$ Bn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
      • Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
      • Market Size and Forecast, By Country, Y-o-Y Growth and By Country,  2018-2030, (US$ Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
      • Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
      • Market Size and Forecast, By Country, Y-o-Y Growth and By Country,  2018-2030, (US$ Bn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
      • Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
      • Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
      • Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region,  2018-2030, (US$ Bn)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Company Profiles
      • Novo Nordisk A/S
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Biocon Limited
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Oramed Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Rani Therapeutics
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Entera Bio Ltd.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Enteris BioPharma, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Chiasma, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Allena Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 30 market data tables and 26 figures on “Global Oral Biologics Market”-Global forecast to 2030

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount
Logo

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo